Derivatives of the β-crinane Amaryllidaceae Alkaloid Haemanthamine as Multi-Target Directed Ligands for Alzheimer's Disease

Eliška Kohelová ¹, Rozálie Peřinová ¹, Negar Maafi¹, Jan Korábečný ^{2,3}, Daniela Hulcová ^{1,4}, Jana Maříková ⁵, Tomáš Kučera ², Loreto Martine-Gonzalez ⁶, Martina Hrabinova ², Katarina Vorčáková ⁷, Lucie Nováková ⁸, Angela De Simone ⁹, Radim Havelek ¹⁰,Lucie Cahlíková ^{1*}

- ¹ ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
- ² Department of Toxicoloxy and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Třebešská 1575, 500 05 Hradec Králové, Czech Republic
- ³ Department Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Králové, Czech Republic
- ⁴ Department of Pharmacognosy, Faculty of Pharmacy, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
- ⁵ Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
- ⁶ Centro de Investigaciones Biológicas-CSIC, Avenida Ramiro de Maeztu 9, 28040 Madrid, Spain
- ⁷ Deaprtment of Biological and Biochemical Sciences, Faculty of Chemical technology, University of Pardubice, Studentská 95, 532 10 Pardubice, Czech Republic
- ⁸ Department of Analytical Chemistry, Faculty of Pharmacy, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
- ⁹ Department for Life Quality Studies, University of Bologna, Corso D'Augusto 237, 47921 Rimini, Italy
- ¹⁰ Department of Medicinal Biochemistry, Faculty of Medicine, Charles University, Zborovská 2089, 500 03 Hradec Králové, Czech Republic
- * Correspondence: cahlikova@faf.cuni.cz; Tel.: +420-495067311; Fax: +420-495067162

Analytical spectra of haemanthamine:

HPLC (UV/VIS)





HPLC/MS





¹³C-NMR

H.F.1.3

date

sw at np fb bs d1 nt ct

TRANSMIT

DECC dn dof dm decwave dpwr dmf

solvent

77.250 76.992 76.742 exp701 CARBON SAMPLE Mar 14 2019 PRESATURATION satmode n n cdcl3 exp solvent exp S file exp S ACQUISITION temp sw 31250.0 gain at 1.049 spin np 6536 hst fb 17000 pw90 bs 1 alfa d1 1.000 2500 wet SPECIAL 25.0 30 20 0.008 11.300 10.000 A ali .00 il 837 in .TER dp cl3 hs 125.705 proc 1913.9 lb 55 fn 5.650 ¥ FLAGS n n y TRANSMITTER tn sfrq 125 tof 19 tpwr pw 5 DECOUPLER nn PROCESSING 2.50 not used DISPLAY 2923.3 5.650 R sp H1 wp 0 rfl yyy rfp w rp 40 lp 10870 16169.5 11479.4 9678.2 -125.3 63.289 62.819 61.142 56.666 132.426 72.599 0 79.891 PLOT 146.623 146.319 wc sc vs th nm 175 134.930 28.015 126.850 178 0 199 50. 2 cdc ph 150 140 130 120 110 100 90 80 70 60 50 40 ppm

Analytical spectra of prepared derivatives:

11-O-Propionylhaemanthamine (1b)

ESI-HRMS



EI-MS

exp109 PROTON

11-O-Pentanoylhaemanthamine (1d)

ESI-HRMS

EI-MS

File :C:\msdchem\1\data\SNAP\3176LC.D Operator :

exp100 PROTON

11-O-Hexanoylhaemanthamine (1e)

ESI-HRMS

EI-MS

File :C:\msdchem\1\data\SNAP\3172LC.D Operator : Acquired : 18 Oct 2016 13:31 using AcqMethod LUCKA_7.M Instrument : GCMS Sample Name: LC-52 Misc Info : Vial Number: 5 Abundance 7000 Average of 29.635 to 29.697 min.: 3172LC.D\data.ms (-) 399.1 6500 6000 5500 224.0 5000 4500 43.0 209.9 4000 269.1 181.0 3500 3000 284.1 2500 240.1 252.1 2000 71.0 1500 153.0 115.0 99.0 1000 55.0 127.9 141.0 167.0 199.1 300.1 370.1 500 311.9 324.1 340.1 356.1 384.1 86.9 415. 0

m/z-> 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380 390 400 410

11-O-Butanoylhaemanthamine (1f)

EI-MS

:C:\msdchem\1\data\SNAP\3444LC.D File Operator : Lucka Acquired : 24 Mar 2017 13:19 using AcqMethod LUCKA_7.M Instrument : GCMS Sample Name: JM-1 Misc Info :

¹H-NMR

exp9 PROTON SAMPLE PRESAT date Nov 10 2015 satmode solvent cdc13 wet file /home/vnm:1/v- SPF nmrsys/data/Zalohy- temp /Hrabalek-160825/N- gain emecek_Jan/Botanik- spin a/JM-1_H.fid hat ACQUISITION px90 PRESATURATION SPECIAL -1_H.fid hst ION pw90 8012.8 alfa 2.045 32768 il 4000 in 32 dp 1.000 hs 8 P 8 fn sw at np fb bs d1 nt ct FLAGS PROCESSING . fn .⊥≤R 499.866 wp 499.9 rfl 60 rfp 4.550 rp IR not used DISPLAY TRANSMITTER tn tn sfrq tof tpwr pw DECOUPLER dn C13 dof 0 dm nnn decwave W40_OneNMR~ PLOT

wc sc vs th ai

cdc ph

_W018 _W018 37 32258

dpwr dmf

11-O-Benzoylhaemanthamine (1g)

ESI-HRMS

EI-MS

¹H-NMR

exp39 PROTON

11-O-(3-chlorobenzoyl)haemanthamine (1h)

ESI-HRMS

EI-MS

11-O-(3-bromobenzoyl)haemanthamine (1i)

ESI-HRMS

EI-MS

11-O-(2-methylbenzoyl)haemanthamine (1j)

ESI-HRMS

EI-MS

File :C:\msdchem\1\data\SNAP\3639LC.D File :C:\msdchem11data\SNAP\3639LC.D Operator : Acquired : 17 Oct 2017 9:58 using AcqMethod LUCKA_7.M Instrument : GCMS Sample Name: LC-90 Misc Info : Vial Number: 9 Abundance Average of 34.838 to 34.925 min.: 3639LC.D\data.ms 119.0 26000 24000 22000 20000 18000 16000 14000 12000 10000 91.0 225.1 8000 268.1 419.2 6000 283.1 4000 210.0 181.0 2000 65.0 242.1 152.1 44.0 300.1 390.1 77.0 139.1 167.1 103.0 256.1 193.0 311.9 327.1 344.1 361.1 374.1 404.1 0 431.1443. 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380 390 400 410 420 430 440 m/z-->

11-O-(3-methoxybenzoyl)haemanthamine (1k)

ESI-HRMS

EI-MS

File :C:\msdchem\1\data\SNAP\3351LC.D Operator : Lucka Acquired : 19 Jan 2017 17:22 using AcqMethod LUCKA_7.M Instrument : GCMS Sample Name: LC-61 Misc Info : Vial Number: 6

11-O-(4-nitrobenzoyl)haemanthamine (1m)

ESI-HRMS

EI-MS

No ionization under EI-MS conditions

Compound	Bibl. ^b	<i>Pe</i> (10 ⁻⁶ cm s ⁻¹) ^c	Prediction		
Atenolol	0,8	0,3 ± 0,3			
Caffeine	1,3	0,1 ± 0,1			
Desipramine	12	7,7 ± 0,4			
Enoxacin	0,9	0,6 ± 0,5			
Hydrocortisone	1,9	0,8 ± 0,2			
Ofloxacin	0,8	0,3 ± 0,1			
Piroxicam	2,5	0,9 ± 0,2			
Promazine	8,8	8,6 ± 0,5			
Testosterone	17	13,6 ± 0,3			
Verapamil	16	15,5 ± 0,8			
18g		8,4 ± 0,2	CNS +		
18j		5,8 ± 0,9	CNS +		
18m		7,1 ± 0,3	CNS +		

Table S1. Permeability (*Pe* 10⁻⁶ cm s⁻¹) in the PAMPA-BBB assay for 10 commercial drugs (used in the experiment validation) and compounds **1g**, **1j** and **1m** with their predictive penetration in the CNS.^a

^aPBS:EtOH (70:30) was used as solvent. ^bReference Di et al. ^cData are the mean ± SD of 2 independent experiments.

Figure S1. Linear correlation between experimental and reported permeability of commercial drugs using the PAMPA-BBB assay.

Table S2. Cell proliferation of haemanthamine derivatives (1a - 1m; c = 10μ M) for 10 human cell lines.

	1	1a	1b	1c	1d	1e	1f	1g	1	1i	1j	1k	1m	DOX
Jurkat	13±3	100±13	104±3	110±3	92±1	100±7	90±12	83±11	69±6	133±10	95±11	83±1	69±7	0±3
MOLT-4	1±1	106±9	97±8	99±8	96±1	97±3	101±18	110±19	135±22	115±15	91±3	94±18	76±12	0±1
A549	30±6	95±9	84±3	84±3	99±7	105±9	106±12	98±2	75±25	122±5	96±8	102±5	74±6	66±16
HT-29	37±6	97±10	79±15	82±17	94±4	100±3	101±3	110±17	97±23	120±4	98±6	93±3	73±2	77±12
PANC-1	37±3	114±4	70±13	85±13	88±3	96±4	99±6	100±10	118±9	108±2	95±6	88±5	71±7	59±9
A2780	30±5	107±17	104±3	123±9	99±2	106±5	104±8	120±10	122±24	162±9	129±11	108±7	86±4	5±1
HeLa	16±2	83±6	69±11	74±8	93±6	98±3	88±3	98±2	72±4	93±5	104±4	84±12	71±1	7±10
MCF-7	11±1	97±19	85±7	103±7	93±5	95±4	96±13	108±10	90±11	105±4	112±3	100±2	62±10	41±7
SAOS-2	28±3	88±6	96±16	85±15	88±6	96±8	104±7	104±9	135±6	97±10	97±17	89±15	69±4	73±8
MRC-5	30±2	113±12	102±13	95±7	89±3	96±4	87±14	101±5	100±5	105±3	112±9	92±1	61±8	40±4

Values represent cell proliferation after haemanthamine analogue treatment and are expressed as percent of proliferation of untreated control cells. Each value is a mean of three independent experiments. Doxorubicin was used as a reference drug.